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ABSTRACT Pulmonary hypertension (PH) is frequent in left heart disease (LHD), as a consequence of
the underlying condition. Significant advances have occurred over the past 5 years since the 5th World
Symposium on Pulmonary Hypertension in 2013, leading to a better understanding of PH-LHD,
challenges and gaps in evidence. PH in heart failure with preserved ejection fraction represents the most
complex situation, as it may be misdiagnosed with group 1 PH. Based on the latest evidence, we propose a
new haemodynamic definition for PH due to LHD and a three-step pragmatic approach to differential
diagnosis. This includes the identification of a specific “left heart” phenotype and a non-invasive
probability of PH-LHD. Invasive confirmation of PH-LHD is based on the accurate measurement of
pulmonary arterial wedge pressure and, in patients with high probability, provocative testing to clarify the
diagnosis. Finally, recent clinical trials did not demonstrate a benefit in treating PH due to LHD with
pulmonary arterial hypertension-approved therapies.
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Introduction
Pulmonary hypertension (PH) is a common complication of left heart disease (LHD), in response to a
passive increase in left-sided filling pressures, more specifically left atrial pressure [1]. It is currently
defined as post-capillary PH, by an increase in mean pulmonary arterial pressure (mPAP) ⩾25 mmHg and
a pulmonary arterial wedge pressure (PAWP) >15 mmHg [2]. In most cases, PH-LHD (group 2 PH) is a
consequence or an abnormal biomarker of the underlying cardiac disorder. However, the structure and
function of the pulmonary circulation may be further affected by several mechanisms potentially leading
to pulmonary arterial and venous remodelling. In heart failure, recent data even suggest that the severity of
PH correlates most strongly with venous and small arteriolar intimal thickening [1–3]. In addition, the
function of the right ventricle is often affected independently from the afterload increase [4–7], leading to
uncoupling of the right ventricle/pulmonary artery unit [8–10] with further exercise limitation and adverse
outcome. This is especially true in heart failure with preserved ejection fraction (HFpEF) [4–11]. Over the
past 5 years since the 5th World Symposium on Pulmonary Hypertension (WSPH) in 2013, significant
advances have improved our understanding of PH-LHD. This article summarises these findings, key
challenges and proposals for the approach to this condition, with a specific focus on PH due to HFpEF.
Definition and classification of PH-LHD
At the 5th WSPH in 2013, a new terminology was adopted to distinguish isolated post-capillary PH
(IpcPH) from combined post-capillary and pre-capillary PH (CpcPH), based on the diastolic pressure
difference/gradient (DPG) between the diastolic PAP (dPAP) and PAWP [1]. However, this definition was
found to be too restrictive and exposed to interpretation, leading to controversies about whether the DPG
would [12–15] or would not [16–21] predict outcome in patients with group 2 PH. Pulmonary vascular
resistance (PVR) was subsequently reintroduced to better reflect the impact of the right ventricle on
outcome [2]. To date, the haemodynamic definition of PH-LHD stands as: 1) post-capillary PH when
mPAP ⩾25 mmHg and PAWP >15 mmHg; 2) IpcPH, when DPG <7 mmHg and/or PVR ⩽3 Wood Units
(WU); and 3) CpcPH when DPG ⩾7 mmHg and/or PVR >3 WU. These two distinct haemodynamic
phenotypes may be further defined by several variables obtained during diagnostic right heart
catheterisation (RHC), none being totally independent from potential limitations [22]. The combination of
recent analyses and basic physiology reveals that the haemodynamic definition of PH-LHD relies heavily
on the accurate measurement of PAWP.
What is a normal PAWP and how to measure it?
In normal individuals, PAWP is close to dPAP, with a mean±SD value of 8.0±2.9 mmHg [23] for a normal
DPG between 0 and 2 mmHg [1, 2, 22]. Therefore, taking into account 2 standard deviations, a value
⩾14 mmHg should be considered abnormal. Accordingly, clinical trials in pulmonary arterial hypertension
(PAH) have historically included patients with PAWP ⩽15 mmHg (in agreement with the 2016
recommendations on heart failure from the European Society of Cardiology [24]) and PVR >3 WU. To
avoid inconsistencies, a common approach to the interpretation of the measurement is necessary. This
includes timing of the measurement with respect to the cardiac and respiratory cycle, relationship with left
ventricular end-diastolic pressure (LVEDP), and other confounding factors, such as the presence of large
v-waves and atrial fibrillation [25]. In the absence of mitral stenosis, PAWP measured at end-diastole
(i.e. typically as the mean of the a-wave or, alternatively, a QRS-gated approach) more closely
approximates LVEDP [25–27]. By contrast, the mean PAWP (averaged throughout the cardiac cycle) in
the presence of large v-waves (mitral regurgitation or non-compliant left atrium) will be higher than
end-diastolic PAWP and will overestimate LVEDP. This contributes to negative DPG values reported in
many studies and may also be observed in atrial fibrillation, when no a-wave is present [28–31]. Since the
v-wave contribution may augment the systolic PAP (sPAP), using the end-diastolic PAWP rather than
mean PAWP may lead to a slight overestimation of PVR in the aforementioned scenarios.
Recommendations for measurement of PAWP/LVEDP in the differential diagnosis of PH
• A value of PAWP >15 mmHg, measured at end-expiration at rest, is considered consistent with
PH-LHD. There is insufficient new data since the 5th WSPH in 2013 to recommend a change in this
cut-off value.
• PAWP should be measured at end-diastole to determine the pre-capillary component of PH-LHD and
the calculation of PVR. In sinus rhythm, this corresponds to the mean of the a-wave. In atrial fibrillation,
it is appropriate to measure PAWP 130–160 ms after the onset of QRS and before the v-wave.
• There are no new data to suggest a change in standards for the measurement of PAWP. Therefore,
we continue to recommend the assessment of PAWP at end-expiration, as averaging over of the
respiratory cycle would reclassify many post-capillary PH patients to pre-capillary disease with
the current PAWP cut-off value.
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• Best practice suggests that RHC should be performed in stable, non-acute clinical conditions for the
differential diagnosis of PH. Proper levelling at the mid-chest and “zero”ing the transducer to
atmospheric pressure are critical. Patients should be positioned supine with legs flat and pressures
recorded during spontaneous breathing (no breath-hold). Measurements should be repeated in
triplicate to obtain values within a 10% agreement.
• If PAWP is elevated and the accuracy of PAWP is in question, blood oxygen saturation should be
determined in the wedge position. If the PAWP oxygen saturation is <90%, direct LVEDP
measurement should be obtained.
• The presence of significant, large v-waves should be noted as this strongly suggests LHD regardless of
resting PAWP.
How to define CpcPH?
Evidence in PH-LHD has been generated since the 5th WSPH in 2013 to 1) characterise the clinical
profile, 2) describe the haemodynamic features and 3) identify outcome predictors. Indeed, the presence
and the identification of a pre-capillary component in post-capillary PH are critical as it may have an
impact on prognosis, can modify management and serves as the basis for clinical trial design [32]. In
addition, CpcPH is associated with a reduced exercise capacity and a phenotype similar to PAH [21, 33].
Finally, it has been recently suggested that CpcPH may present a genetic profile that could be different
from IpcPH [16].
Nevertheless, the populations studied in these retrospective registries are heterogeneous, from pure heart
failure with reduced ejection fraction (HFrEF) cohorts [16–18], all causes of LHD [12, 15, 20, 21, 28, 34], to
pure valvular heart disease (VHD) registries [13, 14]. The typical profile of PH-LHD combines an elevated
PAWP (>20 mmHg), a mildly elevated mPAP (25–40 mmHg), a low cardiac index (⩽2.5 L·min−1·m−2), an
elevated transpulmonary pressure gradient (TPG) (>12 mmHg), a normal DPG (<3 mmHg) and PVR
ranging from 3 to 4.9 WU. In addition, right atrial pressure is consistently elevated (>10 mmHg), which
may, together with elevated PAWP, suggest fluid overload or pericardial constraint. Finally, most studies
reported a significant proportion (roughly one-third) of negative DPG that may be explained by the
aforementioned limitations [27]. This is in keeping with a high rate of atrial fibrillation, affecting around
40% of patients.
The search for an ideal predictor of outcome in PH-LHD has led to conflicting results. On multivariate
analysis, several predictors were found: a combination of mPAP and PVR [13, 16], pulmonary arterial
compliance (PAC) either alone [19, 20] or in combination with mPAP and PAWP [16], or a combination
of mPAP and DPG [12]. A meta-analysis identified 10 retrospective analyses using PVR, DPG and/or PAC
to predict survival in PH-LHD [35]. For the purpose of consistency, and to better individuate the risk
associated with each variable, independently of arbitrary cut-offs, only studies reporting the prognostic
power of continuous variables were included. The analysis was done on a total of 2513 patients, followed
for up to 15 years. The haemodynamic profile revealed average values of mPAP, PVR, DPG and PAC of
35 mmHg, 3.0 WU, 1.2 mmHg and 2.5 mL·mmHg−1, respectively. In this analysis, DPG, PVR and PAC
appeared to be associated with survival. However, both PVR and PAC were stronger predictors of outcome
when compared with DPG [35]. It was suggested that a combination of variables might be better than an
isolated value for prognosis purposes [35]. Interestingly, a recent analysis of three large US cohorts showed
that higher pulmonary artery elastance and lower PAC are associated with increased mortality and right
ventricular dysfunction, across the spectrum of heart failure and even when resistive load was normal [36].
This strongly suggests that, in CpcPH due to heart failure, the total right ventricular load is closely linked
to outcome. Finally, a recent large retrospective analysis of 2587 patients with PH-HFpEF showed that
TPG ⩾12 mmHg, PVR ⩾3 WU and DPG ⩾12 mmHg were predictors of mortality and heart failure
hospitalisations [37].
Therefore, the best way to describe the pre-capillary component of post-capillary PH remains
controversial; none of the haemodynamic variables proposed to describe PH-LHD [22] are free from
limitations.
Recommendations
• After careful consideration of the changes in the general definition of PH [36], the proposed
haemodynamic definition of PH in LHD is: 1) IpcPH: PAWP >15 mmHg and mPAP >20 mmHg and
PVR<3 WU; and 2) CpcPH: PAWP >15 mmHg and mPAP >20 mmHg and PVR ⩾3 WU.
• Beyond a strict haemodynamic definition, other markers of disease may be taken in consideration to
better determine a patient’s prognosis. These could include an additional haemodynamic marker (e.g.
DPG or PAC), cardiopulmonary exercise testing (CPET) profile (level of V′E/V′CO2 (minute
ventilation/oxygen uptake) slope, exercise oscillatory ventilation, end-tidal carbon dioxide tension
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(PETCO2)), indices of right ventricular function and right ventricle/pulmonary artery coupling
(compliance and elastance) and biomarkers. In the context of PH due to HFpEF, ST2, a member of
the interleukin-1 superfamily, may be complementary to N-terminal pro-brain natriuretic peptide
(NT-proBNP) [24].
• Given the limitations of pure haemodynamic definitions, future studies should be aimed at developing
biomarkers and other non-haemodynamic diagnostics to discriminate IpcPH and CpcPH.
Diagnostic approach and differential diagnosis of PH-LHD
Although RHC is the gold standard for the diagnosis of PH, it is not sufficient to make a clear distinction
between idiopathic PAH (IPAH) and PH-LHD, especially when risk factors or documented history of
cardiovascular disease (CVD) coexist [1, 2, 32, 34, 38]. Therefore, we propose a three-step approach to
the differential diagnosis: 1) identification of a clinical phenotype to establish the characteristics of
group 2 PH, 2) determination of a pre-test probability to identify which patients should move to an
invasive evaluation and 3) haemodynamic characterisation, which could include provocative testing in
selected cases.
Clinical phenotype of PH due to LHD
The revised clinical classification distinguishes three main entities in group 2 PH [38]: 1) PH due to
HFpEF, 2) PH due to HFrEF and 3) PH due to VHD. In contrast to the other aetiologies, the distinction
between PH due to HFpEF, PAH and chronic thromboembolic PH (CTEPH) may be challenging. Indeed,
traditional cardiovascular risk factors may be present in patients with PAH [32, 34, 39]. Patients with
systemic sclerosis may present with left ventricular involvement, independent from the presence of PH and
pulmonary vascular disease (PVD) [40]. In patients with CTEPH, PAWP may be difficult to measure due
to pulmonary artery obstruction and LVEDP may be elevated as patients may have concomitant cardiac
involvement [41]. Finally, patients with HFpEF [32] and PH due to HFpEF [42] may present with a low
diffusing capacity of the lung for oxygen (DLCO), an independent predictor of outcome [43]. All these
potential confounding factors may lead to misclassification of PH.
The latter may be avoided by combining factors that are typically associated with group 2 PH, which include
clinical features, echocardiographic abnormalities and other tests (e.g. magnetic resonance imaging and
CPET) [1, 2, 39]. Interestingly, the prevalence of such risk factors in the COMPERA registry is high,
particularly in an older subgroup of patients with cardiovascular comorbidities (referred to as “atypical
PAH”) and in patients with PH due to HFpEF [34]. Importantly, a high rate of atrial fibrillation was reported
at the time of diagnosis in IPAH, “atypical PAH” and PH due to HFpEF, in 10%, 42% and 54%, respectively.
Pre-test probability of PH due to LHD
As a single variable will unlikely be sufficient for accurate differential diagnosis, a combination of the
previous features may help to determine a pre-test probability of group 2 PH. Composite scores integrating
clinical and non-clinical features were derived from retrospective single-centre analyses [44–48], lacking
external validation. A proposal to integrate these features is shown in table 1, some being markers of high
probability of PH-LHD (previous cardiac interventions, presence of atrial fibrillation at diagnosis, evidence
for structural LHD and CPET abnormalities). This approach is in line with the current strategy for the
general diagnosis of PH [2, 49] and has also recently been suggested in the assessment of HFpEF [50].
Haemodynamic evaluation of PH-LHD
As a general rule, the decision for invasive confirmation of PH-LHD assumes the presence of an
intermediate to high probability of PH based on symptoms and echocardiographic features, following the
revised diagnostic algorithm [51]. In patients with a high probability of LHD as a cause of PH, the general
management should be guided according to the recommendation for the underlying condition. In patients
with an intermediate probability, invasive characterisation may be performed in patients with risk factors
for PAH (e.g. systemic sclerosis), CTEPH or in cases of unexplained dyspnoea. The presence of right
ventricular abnormalities also requires invasive assessment as it may have an influence on management
(figure 1a). Due to the presence of multiple confounding factors and the complexity of the interpretation
of invasive measurements, RHC should be performed in expert centres [2]. Provocative testing during
RHC may be useful in the distinction between healthy subjects and HFpEF [51–54] or to uncover
PH-LHD in patients with PAWP at the upper limit of normal (ULN) (i.e. 13–15 mmHg) [55–58]. For this
purpose, both exercise testing and fluid loading are used in clinical practice (table 2).
The ULN of mPAP during an incremental dynamic exercise challenge has been suggested at >30 mmHg
with a cardiac output (CO) <10 L·min−1, which corresponds to a total pulmonary vascular resistance
(TPR=mPAP/CO) of 3 WU [59, 60]. The ULN of PAWP during exercise is thought to be between 15 and
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25 mmHg, but higher values can be recorded in elderly subjects [59, 60]. In addition, other factors may
influence the interpretation of PAWP during exercise, including body position (supine versus upright, with
supine values being 5 mmHg higher than upright on average), age, sex, duration of exercise and timing
over the respiratory cycle [60, 61–64]. Many of these issues are discussed in a recent position paper [60].
Recent data suggest that initial increases in PAWP and mPAP in middle-aged healthy individuals do not
necessarily reflect abnormal cardiopulmonary physiology, as pressures may normalise within minutes [61].
The ULN to detect an abnormal response of PAWP to exercise is therefore unknown. Some authors
suggest a cut-off value of 25 mmHg for the diagnosis of heart failure [51–54], although PAWP >25 mmHg
has been found in elderly individuals free of apparent CVD [61]. Finally, different cut-offs may be used
according to age and sex [55, 62, 63]. Therefore, a flow-adjusted measure of PAWP may be more
appropriate than PAWP alone [59, 60], with recent work suggesting a PAWP/CO slope
>2 mmHg·L−1·min−1 is associated with reduced functional capacity, higher NT-proBNP and reduced heart
failure-free survival [61].
As measurements of pressures during exercise are technically difficult and require specialised equipment, a
fluid challenge may be easier to standardise and more readily available. Any condition associated with
reduced left ventricular diastolic compliance or VHD will be associated with a rapid increase in PAWP
when challenged with an increased systemic venous return [53, 54]. Although not as profound, fluid
loading also increases PAWP in healthy volunteers as a function of age, sex, amount infused and infusion
rate [52]. Thus, the standardisation of the test cut-off values for PAWP has raised controversies [53–55,
65, 66]. It has been shown that up to 20% of patients with pre-capillary PH may present an increase in
PAWP >15 mmHg after fluid loading [56, 57, 65]. However, current evidence suggests a PAWP of
18–20 mmHg after infusion might represent the ULN (table 2) [53, 66]. The advantages and limitations of
exercise testing and fluid loading are presented in table 3.
Recommendations
• The nomenclature of “PAH with cardiovascular risk factors” should be preferred over any other, to
account for their coexistence without suggesting that risk factors may be influencing the cause of the
PVD. The role of comorbidities in the disease process of PAH is not demonstrated and remains unclear.
• A three-step approach should be followed to perform the differential diagnosis between group 2 PH
(mainly HFpEF) and PAH: 1) identification of a clinical phenotype suggesting PH-LHD, 2)
determination of a pre-test probability for PH-LHD and 3) haemodynamic characterisation.
• Invasive assessment should be performed in patients with intermediate probability of PH-LHD,
presence of right ventricular abnormality and when risk factors for PAH/CTEPH coexist (figure 1b).
• In patients with a PAWP 13–15 mmHg and high/intermediate probability of PH-HFpEF, provocative
testing should be considered to uncover PH due to HFpEF. For technical reasons and reliability of
pressure recording, a fluid challenge is preferred over exercise in the approach to differential diagnosis.
• PAWP >18 mmHg immediately after administration of 500 mL of saline over 5 min is considered
abnormal.
TABLE 1 Pre-test probability of left heart disease (LHD) phenotype
Feature High probability Intermediate probability Low probability
Age >70 years 60–70 years <60 years
Obesity, systemic hypertension,
dyslipidaemia, glucose
intolerance/diabetes
>2 factors 1–2 factors None
Previous cardiac intervention# Yes No No
Atrial fibrillation Current Paroxysmal No
Structural LHD Present No No
ECG LBBB or LVH Mild LVH Normal or signs of RV strain
Echocardiography LA dilation; grade >2 mitral flow No LA dilation; grade <2 mitral flow No LA dilation; E/e′ <13
CPET Mildly elevated V′E/V′CO2 slope; EOV Elevated V′E/V′CO2 slope or EOV High V′E/V′CO2 slope; no EOV
Cardiac MRI LA strain or LA/RA >1 No left heart abnormalities
LBBB: left bundle branch block; LVH: left ventricular hypertrophy; RV: right ventricular; LA: left atrial; E/e′: early mitral inflow velocity/mitral
annular early diastolic velocity ratio; CPET: cardiopulmonary exercise testing; V′E: minute ventilation; V′CO2: carbon dioxide production; EOV:
exercise oscillatory ventilation; MRI: magnetic resonance imaging; RA: right atrial. #: coronary artery and/or valvular surgical and/or
non-surgical procedures, including percutaneous interventions.
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• However, how this should impact management is unknown. If PAH-specific therapies are initiated in
patients with an “abnormal” response, caution should be exercised, including close monitoring of
response and side-effects.
Clinical trials and therapy for PH due to LHD
Pathways involved in the development of PAH may contribute to the pathogenesis of heart failure and PH
due to LHD, providing a rationale for investigating the role of their modulation in this setting [1, 2, 32, 39].
Until recently, most studies were performed in HFrEF patients, leading to disappointing results [1, 2, 32, 39].
The results of the ENABLE trials with bosentan were recently published, confirming that blocking
endothelin-1 has no effect on outcome in patients with HFrEF [67]. The SOCRATES programme assessed
the role of vericiguat, a guanylate cyclase stimulator, in HFrEF [68] and HFpEF [69]. In SOCRATES-
Reduced, vericiguat did not change the NT-proBNP level at 12 weeks compared with placebo [68]. Similar
results were observed in SOCRATES-Preserved, with no effect on left atrial volume index, the coprimary
end-point [69]. Inhaled sodium nitrite has been shown to acutely decrease left-sided filling pressures and
PAP at rest [70] and exercise [71]. However, the multicentre INDIE-HFpEF trial (ClinicalTrials.gov identifier
NCT02742129) did not show a benefit of the compound on exercise capacity in HFpEF after 12 weeks [72].
Since 2013, several randomised controlled trials have been completed in patients with PH-LHD (table 4).
The effects of 60 mg sildenafil 3 times a day were compared with placebo in 52 patients with PH due to
HFpEF at 12 weeks [73]. No effect was observed on the primary end-point of mPAP, while a decrease in
PVR and an improvement in exercise capacity were previously shown in a single-centre trial [74]. Riociguat,
a guanylate cyclase stimulator, did not improve mPAP after 12 weeks in patients with PH due to HFrEF [75].
Consider RHC
in selected cases#
Management of 
LHD
No RV abnormality
Intermediate
Pre-test probability of PH-HFpEFa)
RHC recommended
RV abnormality
(imaging, ECG)
High
PAWP 13–15 mmHg
Pre-capillary PH
Low probability
b)
PH-HFpEF
not excluded
1) Consider provocative testing
2) Consider other cardiac testing+
Consider LVEDP
validation+
Intermediate or
high probability
PAWP >15 mmHg
PH-HFpEF likely
Low probability
RHC at expert centres¶
PH-HFpEF 
confirmed
Intermediate or
high probability
FIGURE 1 Haemodynamic assessment of pulmonary hypertension (PH) due to heart failure with preserved
ejection fraction (HFpEF). RV: right ventricular; RHC: right heart catheterisation; LHD: left heart disease;
PAWP: pulmonary arterial wedge pressure; LVEDP: left ventricular end-diastolic pressure; CTEPH: chronic
thromboembolic PH. a) Pre-test probability of PH-LHD is based on the features presented in table 1. RHC is
recommended in intermediate probability when risk factors of pulmonary arterial hypertension/CTEPH are
present and/or if there is evidence of right ventricle abnormality. If the probability is high, patients should be
managed according to recommendations for LHD. b) For the assessment of PH, RHC should be performed at
expert centres. In patients with intermediate/high probability (table 1) and PAWP between 13 and 15 mmHg,
PH-HFpEF is not excluded; provocative testing (tables 2 and 3) should be considered. #: for patients with
systemic sclerosis, risk factors for CTEPH and/or unexplained dyspnea; ¶: after [2]; +: if PAWP >15 mmHg,
LVEDP validation should be considered.
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The MELODY-1 study was the only study specifically including patients with CpcPH [76]. Patients were
randomised to placebo or macitentan 10 mg. The main end-point assessed a composite of significant fluid
retention (weight gain ⩾5% or ⩾5 kg because of fluid overload or parenteral diuretic administration) or
worsening in New York Heart Association Functional Class (NYHA FC) from baseline to end of
treatment. Exploratory end-points included changes in NT-proBNP and haemodynamics at week 12.
Treatment with macitentan was associated with a 10.1% increased risk of fluid retention versus placebo,
mostly within the first month. At week 12, the macitentan group showed no change in PVR, mean right
atrial pressure or PAWP with respect to placebo.
Finally, the SIOVAC trial aimed to determine whether treatment with sildenafil improves outcomes of
patients with persistent PH after correction of VHD [77]. Patients who had undergone a successful valve
replacement or repair procedure at least 1 year before inclusion were randomised to 40 mg sildenafil 3
times daily (n=104) versus placebo (n=96) for 6 months. The primary end-point was a composite clinical
score combining death, hospital admission for heart failure, change in NYHA FC and patient global
self-assessment. Improvement in the clinical score was significantly more frequent in the placebo group
(44 versus 27 patients receiving sildenafil). In contrast, worsening was more common in the sildenafil
group (33 versus 14 patients in the placebo group). The Kaplan–Meier estimates for survival without
admission due to heart failure were 0.76 and 0.86 in the sildenafil and placebo group, respectively,
although this did not reach statistical significance.
The typical profile of patients included in the trials modulating the nitric oxide/cGMP pathway shows an
elderly (70 years) female predominance, with a high rate of atrial fibrillation at baseline (44–77%) and
TABLE 2 Pulmonary arterial wedge pressure (PAWP) response to exercise in normal and heart failure with preserved ejection
fraction (HFpEF), and response to fluid loading in normal, HFpEF and pulmonary hypertension (PH)
First author
[ref.]
Subjects n Age (sex) Protocol Average PAWP: rest
to peak mmHg
Comment
Exercise
WRIGHT [62] 28 healthy 55 years (12 female) Semi-upright 11±3–22±5 early to 17
±6 late
Time-variant changes, early
increase and late decrease
WOLSK [63] 62 healthy 20–80 years
(50% female)
Supine 8–10 rest;
16 leg raising;
19 at 25% peak V′O2;
23 at 75% peak V′O2
35% elderly had PAWP
>25 mmHg
ANDERSEN [52] 26 (14
HFpEF, 12
controls)
70 years HFpEF (57%
female); 63 years
controls (58% female)
Supine exercise
versus fluid loading
Control: 7±3–13±5;
HFpEF: 14±3–32±6
Similar increase in healthy
subjects; 2-fold increase in all
filling pressures during exercise
versus fluid loading in HFpEF
Fluid loading
FUJIMOTO [53] 60 healthy;
11 HFpEF
Young: <50 years;
older: ⩾50 years
100–200 mL·min−1 Young: 10±2–16±2;
older: 9±2–17±2;
HFpEF: 14±4–20±4
Normals reach PAWP 18–19
mmHg
ANDERSEN [52] 26 (14
HFpEF, 12
controls)
70 years HFpEF
(57% female); 63 years
controls (58% female)
10 mL·kg−1·min−1
saline (150 mL·min−1)
Control: 7±3–13±5;
HFpEF: 14±3–21±4
Similar increase of PAWP in
healthy subjects
FOX [55] 107 SSc with
PH suspicion
59 years PAH
(94% female); 66 years
OPVH (64% female)
500 mL saline
(5–10 min)
PAH: 8±3–12±2
(LVEPD 9–12);
OPVH: 12±3–17±5
(LVEDP 15–21)
Retrospective analysis; OPVH
defined by increase in PAWP
>15 mmHg
ROBBINS [57] 207 PAH 51 years PAH
(82% female); 57 years
OPVH (74% female)
500 mL saline
(5–10 min)
PAH: 9±3–11±4;
OPVH: 12±2–19±3
Retrospective analysis; 30% had
increase in PAWP >15 mmHg,
predominantly female, mostly in
normal range
D’ALTO [65] 212 PH
evaluation
58 years pre-capillary
(68% female);
65 years post-capillary
7 mL·kg−1 rapid
infusion
PAH: 9±2–12±2;
HPH: 11±2–22±3
Overlap between groups; cut-off
for PAWP abnormal response at
18 mmHg
V′O2: oxygen uptake; SSc: systemic sclerosis; PAH: pulmonary arterial hypertension; LVEDP: left ventricular end-diastolic pressure; OPVH: occult
pulmonary venous hypertension (defined as PAWP >15 mmHg after fluid loading); HPH: hidden pulmonary hypertension due to left heart disease.
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preserved ejection fraction in more than half of the cases. With the exception of the MELODY trial,
patients had IpcPH, as shown by a combination of DPG around 2 mmHg and PVR below or slightly
above 3 WU [73, 75, 77]. In contrast, the patients recruited in the MELODY trial had a typical CpcPH
profile, which was associated with higher baseline NT-proBNP, reflecting worse right ventricular function
[76]. Several studies using PAH therapies/pathways in PH-LHD are underway (table 5).
PH and vasoreactivity testing in end-stage heart failure
In the context of heart transplantation, PH is associated with an increased 30-day mortality in patients
with TPG >15 mmHg and PVR >5 WU [78]. A continuous risk of morbidity and mortality increases with
progressive elevation in mPAP, TPG and PVR [79]. Finally, PH reverses soon after heart transplantation,
the most pronounced reduction in PVR occurring within 1 month post-transplant [80]. Implantation of a
left ventricular assist device (LVAD) rapidly reduces “fixed” PH in heart transplant candidates, with
survival outcomes comparable to patients without [81]. In addition, right ventricular afterload almost
always declines with LVAD insertion and does so rapidly [82]. It is therefore recommended to perform
RHC in all candidates before listing and at 3–6-month intervals in listed patients, especially in the
presence of reversible PH or worsening heart failure [83]. LVAD recipients with at least one post-implant
RHC without PH likely require less frequent assessments [84]. The current recommendations for heart
transplantation suggest that an acute vasodilator challenge should be performed if sPAP >50 mmHg, and
either TPG ⩾15 mmHg or PVR >3 WU and systemic systolic arterial pressure >85 mmHg [83]. However,
TABLE 3 Limitations and advantages of exercise testing and fluid loading in the assessment of pulmonary hypertension
Exercise testing Fluid loading
Clinical relevance for
symptom assessment
+++ +
Clinical relevance for
differential diagnosis
+ +++
Main advantages Respects the pathophysiology; comprehensive test,
allowing for additional insights in pulmonary vascular
disease (dynamic pulmonary vascular resistance);
complementary with cardiopulmonary exercise testing
Easy to perform, no specific setting; minimal risk of
misinterpretation of pressures reading; better
established cut-off defining abnormal increase in
pulmonary arterial wedge pressure
Main limitations Requires a specific complex setting; expertise in
conducting the test; pressure reading during exercise;
range of normal response uncertain
Unknown response in disease state; age dependency of
response
Standardised protocol +/− ++
TABLE 4 Recently completed randomised controlled trials targeting the phosphodiesterase type 5 inhibitor/nitric oxide and
endothelin pathways in pulmonary hypertension due to left heart disease
First author or
study [ref.]
Study
drug
Dose Subjects
n
Duration Population Primary outcome Result
GUAZZI [74] Sildenafil 50 mg
3 times a day
44 12 months HFpEF PVR,
RV performance,
CPET
Improvement
LEPHT [75] Riociguat 0.5, 1 or 2 mg
3 times a day
201 16 weeks HFrEF mPAP versus
placebo
No change
HOENDERMIS [73] Sildenafil 60 mg
3 times a day
52 12 weeks HFpEF mPAP versus
placebo
No change
SIOVAC [77] Sildenafil 40 mg
3 times a day
231 24 weeks VHD Composite clinical
score#
Worsening in active
group
MELODY-1 [76] Macitentan 10 mg
once daily
48 12 weeks HF (EF >30%);
75% HFpEF
Safety and
tolerability
+10% fluid retention
in active group
HF: heart failure; pEF: preserved ejection fraction; PVR: pulmonary vascular resistance; RV: right ventricular; CPET: cardiopulmonary exercise
testing; rEF: reduced ejection fraction; mPAP: mean pulmonary arterial pressure; VHD: valvular hear disease. #: combination of death,
hospitalisation for HF, change in New York Heart Association Functional Class and patient global self-assessment.
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there is no specific recommendation on the agent to be used. Outside of this setting, the role of
vasoreactivity testing does not clearly predict outcome in PH-LHD [1, 2, 20]. Finally, there is a paucity
of evidence supporting the use of PAH-approved therapies in patients awaiting heart transplantation
and/or LVAD.
Recommendations
• There is still no multicentre trial that suggests targeting PH-LHD with PAH-specific drugs is
beneficial. Therefore, we maintain a strong recommendation against the use of PAH therapies in group
2 PH.
• In addition, a safety signal should be acknowledged: 1) the use of sildenafil in the context of PH
post-VHD intervention is associated with an increased risk of clinical deterioration and death, and 2)
the use of macitentan in CpcPH due to heart failure is associated with an increased risk of fluid
retention.
• Following the MELODY-1 trial, new standards have been proposed to explore the role of
PAH-approved therapies in the context of group 2 PH. If pursued, such trials should be limited to PH
due to HFpEF with CpcPH. The agent of choice should ideally be a HFpEF disease-modifying drug.
Finally, a proof-of-concept study should be performed first, with safety and tolerability, haemodynamic
and/or CPET efficacy end-points.
• Vasoreactivity testing is not recommended in patients with PH-LHD, outside of the context of
assessment for heart transplantation.
Conclusions
PH is common in LHD; it is not a disease, although a subset of patients present with significant
pulmonary vascular changes. Clinical research and prospective long-term multicentre analysis of
PH-HFpEF cohorts may help to better identify risk factors for CpcPH and provide insights on outcome
predictors. A pre-test probability assessment of LHD should be part of the diagnostic approach of PH.
Further studies are needed to develop a multidimensional prediction score. Invasive confirmation on RHC
requires attention to accurate resting PAWP measurement, at end-diastole and end-expiration. An increase
of PAWP >18 mmHg after fluid loading, in patients with resting values between 13 and 15 mmHg and
TABLE 5 Planned and ongoing trials in pulmonary hypertension (PH) due to left heart disease
Study# Study drug Dose Subjects
n
Duration Population Primary outcome
SERENADE
(NCT03153111)
Macitentan 10 mg
once daily
300 52 weeks LVEF ⩾40% and ESC-defined
HFpEF; HF hospitalisation within
12 months and/or PAWP or
LVEDP >15 mmHg within
6 months; elevated NT-proBNP;
PVD or RVD
% change from baseline in
NT-proBNP at week 24
SOPRANO
(NCT02554903)
Macitentan 10 mg
once daily
78 12 weeks LVAD within 45 days; PH by RHC
with PAWP ⩽18 mmHg and
PVR >3 WU
PVR ratio of week 12
to baseline
DYNAMIC
(NCT02744339)
Oral riociguat 1.5 mg
3 times a day
114 26 weeks HFpEF; mPAP >25 mmHg and
PAWP >15 mmHg
Change in CO
Oral treprostinil
(NCT03037580)
Oral
treprostinil
310 24 weeks LVEF ⩾50%; RHC within 90 days
of randomisation; 6MWD >200 m
Change in 6MWD from
baseline to week 24
PASSION (not
registered)
Oral tadalafil 40 mg
once daily
320 NA HFpEF; PH with PAWP
>15 mmHg and mPAP >25 mmHg
and PVR >3 WU
Time to first event defined as
HF-associated hospitalisation
(independently adjudicated)
or death from any cause
#: ClinicalTrials.gov identifier numbers are provided where possible. LVEF: left ventricular ejection fraction; ESC: European Society of
Cardiology; HF: heart failure; pEF: preserved ejection fraction; PAWP: pulmonary arterial wedge pressure; LVEDP: left ventricular end-diastolic
pressure; NT-proBNP: N-terminal pro-brain natriuretic peptide; PVD: pulmonary vascular disease; RVD: right ventricular dysfunction; LVAD:
left ventricular assist device; RHC: right heart catheterisation; PVR: pulmonary vascular resistance; mPAP: mean pulmonary arterial pressure;
CO: cardiac output; 6MWD: 6-min walk distance; NA: not available.
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intermediate/high probability of HFpEF, may be considered abnormal. However, we strongly encourage
further study of this population as well as non-haemodynamic, alternative strategies to differentiate IpcPH
and CpcPH. The CpcPH haemodynamic presentation is now defined by PVR >3 WU on top of a
post-capillary PH phenotype. Finally, multicentre randomised trials using PAH therapies in PH-LHD have
not demonstrated benefit and have raised safety concerns. Their use is still not recommended in PH-LHD.
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